e-Drug3D

1526

RUXOLITINIB

INN
RUXOLITINIB

cas 941678-49-5

CLASS

ANTINEOPLASTIC AGENT
MYELOFIBROSIS
PROTEIN KINASE INHIBITOR

ROUTE (list)

ORAL TOPICAL

ATC code

D11AH09
L01EJ01

PK parameters

VD 59 LITER
Cl 19.9 LITER / HOUR
PPB 97 PERCENT
t1/2 3 HOUR

Solubility

SOLUBLE IN AQUEOUS BUFFERS ACROSS A PH RANGE OF 1 TO 8

Target

TARGET JANUS ASSOCIATED KINASES
JAK1
JAK2

PDB
4U5J (C-SRC IN COMPLEX WITH RUXOLITINIB)

Ligand code = RXT (link to the list of PDB complexes)

Download experimental 3D coordinates of RXT with added hydrogens

DrugCentral

Tyrosine-protein kinase JAK1 UNIPROT P23458 JAK1

Tyrosine-protein kinase JAK2 UNIPROT O60674 JAK2

Download SDF file

(R)-3-(4-(7H-pyrrolo[2,3d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

Formula:
C17H18N6

Calculated chemical properties:

MW 306.37
NB_atoms 23
XLogP 3.47
PSA 68.812
NB_HD 1
NB_HA 6
fsp3 0.41
Lipinski(0=no;1=yes) 1

FDA
NDA 202192 (pdf not found) INN (RUXOLITINIB PHOSPHATE) JAKAFI (INCYTE CORP) APPROVAL= AP YEAR= 2011 NEWMOLECULARENTITY
NDA 215309 (pdf not found) INN (RUXOLITINIB PHOSPHATE) OPZELURA (INCYTE CORP) APPROVAL= AP YEAR= 2021 NEWAPPLICATION
NDA 217900 (pdf not found) INN (RUXOLITINIB PHOSPHATE) LEQSELVI (SUN PHARM INDS INC) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY